Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Depomed Announces Second Quarter 2017 Financial Results
August 7, 2017 4:01 PM EDT- Updates Full-Year Financial Guidance -
- Second Quarter Revenues of $100 million -
- Increases Neurology Salesforce Effective September 1 -
- Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below -
NEWARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended June 30, 2017 and provided an update to the business.
Our second quarter product revenue was broadly in line with our expectations, said Arthur Higgins, President and CEO of Depomed. We... More
